Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia
- PMID: 18342993
- PMCID: PMC2775454
- DOI: 10.1016/j.annemergmed.2008.01.003
Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia
Abstract
Study objective: The Pneumonia Severity Index and CURB-65 predict outcomes in community-acquired pneumonia but have limitations. Procalcitonin, a biomarker of bacterial infection, may provide prognostic information in community-acquired pneumonia. Our objective is to describe the pattern of procalcitonin in community-acquired pneumonia and determine whether procalcitonin provides prognostic information beyond the Pneumonia Severity Index and CURB-65.
Methods: We conducted a multicenter prospective cohort study in 28 community and teaching emergency departments. Patients presenting with a clinical and radiographic diagnosis of community-acquired pneumonia were enrolled. We stratified procalcitonin levels a priori into 4 tiers: I: less than 0.1; II: greater than 0.1 to less than 0.25; III: greater than 0.25 to less than 0.5; and IV: greater than 0.5 ng/mL. Primary outcome was 30-day mortality.
Results: One thousand six hundred fifty-one patients formed the study cohort. Procalcitonin levels were broadly spread across tiers: 32.8% (I), 21.6% (II), 10.2% (III), and 35.4% (IV). Used alone, procalcitonin had modest test characteristics: specificity (35%), sensitivity (92%), positive likelihood ratio (1.41), and negative likelihood ratio (0.22). Adding procalcitonin to the Pneumonia Severity Index in all subjects minimally improved performance. Adding procalcitonin to low-risk Pneumonia Severity Index subjects (classes I to III) provided no additional information. However, subjects in procalcitonin tier I had low 30-day mortality, regardless of clinical risk, including those in higher risk classes (1.5% versus 1.6% for those in Pneumonia Severity Index classes I to III versus classes IV/V). Among high-risk Pneumonia Severity Index subjects (classes IV/V), one quarter (126/546) were in procalcitonin tier I, and the negative likelihood ratio of procalcitonin tier I was 0.09. Procalcitonin tier I was also associated with lower burden of other adverse outcomes. Similar results were observed with CURB-65 stratification.
Conclusion: Selective use of procalcitonin as an adjunct to existing rules may offer additional prognostic information in high-risk patients.
Figures
Comment in
-
Risk stratification of community-acquired pneumonia: what does all of this mean?Ann Emerg Med. 2008 Jul;52(1):61-2. doi: 10.1016/j.annemergmed.2008.02.018. Epub 2008 Apr 3. Ann Emerg Med. 2008. PMID: 18387703 No abstract available.
-
Annals of Emergency Medicine Journal Club. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.Ann Emerg Med. 2008 Jul;52(1):59-60. doi: 10.1016/j.annemergmed.2008.05.033. Ann Emerg Med. 2008. PMID: 18565380
-
Annals of Emergency Medicine Journal Club. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia answers to the July 2008 Journal Club questions.Ann Emerg Med. 2008 Dec;52(6):754-63. doi: 10.1016/j.annemergmed.2008.07.010. Ann Emerg Med. 2008. PMID: 19027500 No abstract available.
Similar articles
-
Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.Respirology. 2016 Feb;21(2):280-8. doi: 10.1111/resp.12704. Epub 2015 Dec 10. Respirology. 2016. PMID: 26662169 Free PMC article. Review.
-
Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.Respir Care. 2014 Apr;59(4):564-73. doi: 10.4187/respcare.02807. Epub 2013 Oct 29. Respir Care. 2014. PMID: 24170911
-
Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.Chest. 2009 Sep;136(3):823-831. doi: 10.1378/chest.08-1981. Epub 2009 Apr 10. Chest. 2009. PMID: 19363212 Free PMC article.
-
Making sense of scoring systems in community acquired pneumonia.Respirology. 2009 Apr;14(3):327-35. doi: 10.1111/j.1440-1843.2009.01494.x. Respirology. 2009. PMID: 19353770 Review.
-
Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.Chest. 2005 Oct;128(4):2223-9. doi: 10.1378/chest.128.4.2223. Chest. 2005. PMID: 16236878
Cited by
-
Changes in the levels of WBC count, PCT, CRP and ESR in Patients with acute Community-acquired Lower Respiratory tract infections and their diagnostic value.Pak J Med Sci. 2024 Jan-Feb;40(3Part-II):405-409. doi: 10.12669/pjms.40.3.7699. Pak J Med Sci. 2024. PMID: 38356842 Free PMC article.
-
Validation of risk prediction for outcomes of severe community-acquired pneumonia among under-five children in Amhara region, Northwest Ethiopia.PLoS One. 2023 Feb 15;18(2):e0281209. doi: 10.1371/journal.pone.0281209. eCollection 2023. PLoS One. 2023. PMID: 36791115 Free PMC article.
-
Severe community-acquired pneumonia.Eur Respir Rev. 2022 Dec 14;31(166):220123. doi: 10.1183/16000617.0123-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36517046 Free PMC article. Review.
-
A biomarker assay to risk-stratify patients with symptoms of respiratory tract infection.Eur Respir J. 2022 Dec 15;60(6):2200459. doi: 10.1183/13993003.00459-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 36104292 Free PMC article.
-
A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics.Hum Vaccin Immunother. 2021 Dec 2;17(12):5460-5474. doi: 10.1080/21645515.2021.1990649. Epub 2021 Nov 10. Hum Vaccin Immunother. 2021. PMID: 34757894 Free PMC article. Review.
References
-
- DeFrances CJ, Podgornik MN. 2004 National Hospital Discharge Survey. Adv Data. 2006;(371):1–19. - PubMed
-
- Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clinical Therapeutics. 1998;20(4):820–837. - PubMed
-
- Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310. - PubMed
-
- Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: Age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165(6):766–772. - PubMed
-
- Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–250. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical